Research

Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study

BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j629 (Published 28 February 2017) Cite this as: BMJ 2017;356:j629

Re: Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study

Dear colleagues
Thank you for your interest in our paper and your valuable remarks. We studied the effect on the newborn of intrauterine exposure to neuraminidase inhibitors and could not find any negative consequences. In the present study we did not have information on the vaccination status of the pregnant women and hence we do not draw any conclusions on the benefit of vaccination versus the benefit of post exposure prophylaxis as the preferable strategy to protect women and infants.
Best Regards, on behalf of the authors
Sophie Graner

Competing interests: No competing interests

20 March 2017
Sophie Graner
MD Consultant Obsts & Gyne
Centre for Pharmacoepidemiology, Karolinska Institutet
Department of Medicine, CPE, Karolinska University Hospital SE 17176 Stockholm, Sweden
Click to like:
81